Moderna, Inc. vs. Novavax, Inc.: cost cuts, vaccine pipeline catalysts, and valuations. Click for this comparison of NVAX and MRNA and see which is better for you.

Context for Novavax after recent share performance Novavax (NVAX) has drawn fresh attention after a recent move in its share ...

The biotech’s licensing pact with Pfizer, revealed last week, will leverage its adjuvant vaccine platform in the development of two undisclosed Pfizer products. After pocketing ...

Experts say ‘they’re just coming up with reasons’ as agency says application lacked ‘adequate and well controlled’ trial ...

Gaithersburg-based Novavax said Tuesday it signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to vaccines for use in up to two infectious diseases, and ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine programs. The tech, called Matrix-M, is designed to trigger an immune ...

Modified agreement also includes the development of an updated vaccine in fall 2023 This contract will support the U.S. government's continued efforts to make Novavax' protein-based vaccine available ...

Novavax faces plenty of uncertainty related to a deal it signed with a larger company. The biotech's pipeline doesn't look that exciting either. 10 stocks we like better than Novavax › Novavax (NASDAQ ...

The Food and Drug Administration authorized Novavax's single-strain vaccine, which targets omicron subvariant XBB.1.5, for emergency use in people ages 12 and up. The Centers for Disease Control and ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The deal would funnel crucial ...

Jan 20 (Reuters) - Novavax ‌said on Tuesday it signed a licensing ‌agreement allowing Pfizer access to its technology that boosts immune responses to vaccines for use in up to two infectious diseases, ...